[New therapeutic strategies in HER2-positive breast cancer]

Benoîte Mery; Philippe Toussaint; Pierre-Etienne Heudel; Armelle Dufresne; Mélodie Carbonnaux; Hélène Vanacker; Thomas Bachelot; Olivier Trédan

doi:10.1016/j.bulcan.2021.04.015

[New therapeutic strategies in HER2-positive breast cancer]

Bull Cancer. 2021 Jun 15:S0007-4551(21)00215-0. doi: 10.1016/j.bulcan.2021.04.015. Online ahead of print.

[Article in French]

Authors

Benoîte Mery¹, Philippe Toussaint¹, Pierre-Etienne Heudel¹, Armelle Dufresne¹, Mélodie Carbonnaux¹, Hélène Vanacker¹, Thomas Bachelot¹, Olivier Trédan²

Affiliations

¹ Centre Léon-Bérard, département de cancérologie médicale, 28, rue Laennec, 69008 Lyon, France.
² Centre Léon-Bérard, département de cancérologie médicale, 28, rue Laennec, 69008 Lyon, France. Electronic address: olivier.tredan@lyon.unicancer.fr.

PMID: 34144793
DOI: 10.1016/j.bulcan.2021.04.015

Abstract

Breast cancer with HER2-amplification accounts for 20% of breast cancers. The management of patients has dramatically changed with the advent of anti-HER2 treatment, especially the monoclonal antibodies since 2000 in the metastatic and (neo)-adjuvant setting, leading to an improvement of patient outcomes. If therapeutic arsenal has been gradually enhanced with the targeting of HER receptors family, resistances to these treatments are observed, hence the development of new therapeutic strategies. This review provides an updated look of novel therapeutic strategies in HER2-positive breast cancer, as well as future perspectives, both in the adjuvant and metastatic setting.

Keywords: Breast cancer; Cancer du sein; Clinical trials; Essais cliniques; HER2 over-expression; HER2-positif; Stratégie thérapeutique; Treatment strategy.

Publication types

English Abstract
Review